SCHEMBL7784202

SCHEMBL7784202

CCNC(=O)CCCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.61
SLC22A6 Q4U2R8 2/20 0.52
TSHR P16473 5/20 0.48
AKR1B1 P15121 1/20 0.48
EPHX2 P34913 2/20 0.47
GPR84 Q9NQS5 7/20 0.46
PPARG P37231 6/20 0.46
PPARD Q03181 6/20 0.46
PPARA Q07869 6/20 0.46
HDAC11 Q96DB2 5/20 0.46
ALDH1A1 P00352 2/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46
PTPN1 P18031 2/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
MEN1 O00255 1/20 0.46
ESR1 P03372 1/20 0.46
ALOX15 P16050 1/20 0.46
PDE4A P27815 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6550198 0.95 FAAH (0.68) FAAHSLC22A6TSHRAKR1B1EPHX2
Hydrochloric Acid SCHEMBL8911650 0.93 FAAH (0.65) FAAHSLC22A6TSHRAKR1B1EPHX2
SCHEMBL14505540 0.93 FAAH (0.72) FAAHSLC22A6TSHRAKR1B1EPHX2
SCHEMBL29215738 0.93 FAAH (0.72) FAAHSLC22A6TSHRAKR1B1EPHX2
SCHEMBL18573655 0.93 FAAH (0.72) FAAHSLC22A6TSHRAKR1B1EPHX2
SCHEMBL12982690 0.93 FAAH (0.72) FAAHSLC22A6TSHRAKR1B1EPHX2
SCHEMBL14505535 0.93 FAAH (0.72) FAAHSLC22A6TSHRAKR1B1EPHX2
SCHEMBL13113451 0.93 FAAH (0.72) FAAHSLC22A6TSHRAKR1B1EPHX2
SCHEMBL12346213 0.90 FAAH (0.73) FAAHTSHREPHX2MEN1KMT2A
Stearic Acid SCHEMBL28613586 0.87 FAAH (0.84) FAAHSLC22A6TSHRAKR1B1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062580-A1 REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT THE PILOT INK CO., LTD. (JP) 2026-03-05 US disclosed
US-12460099-B2 Reversibly thermochromic composition, reversibly thermochromic microcapsule pigment encapsulating reversibly thermochromic composition, and writing instrument using reversibly thermochromic microcapsule pigment THE PILOT INK CO., LTD. (JP) 2025-11-04 US disclosed
EP-3608386-B1 REVERSIBLY THERMOCHROMIC COMPOSITION, AND REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT HAVING SAME ENCLOSED THEREIN PILOT INK CO LTD (JP) 2025-02-19 EP disclosed
US-12123107-B2 Reversibly thermochromic composite fiber KABUSHIKI KAISHA PILOT CORPORATION (JP) 2024-10-22 US disclosed
CN-113646052-B Reversible thermochromic composition, reversible thermochromic microcapsule pigment, and writing instrument 百乐墨水株式会社 2024-05-17 CN disclosed
US-20220169919-A1 REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT THE PILOT INK CO., LTD. (JP) 2022-06-02 US disclosed
EP-3950068-A1 REVERSIBLE THERMOCHROMIC COMPOSITION, REVERSIBLE THERMOCHROMIC MICROCAPSULE PIGMENT COMPRISING SAME, AND WRITING INSTRUMENT USING SAME THE PILOT INK CO., LTD. (JP) 2022-02-09 EP disclosed
US-20210355608-A1 REVERSIBLY THERMOCHROMIC COMPOSITE FIBER THE PILOT INK CO., LTD. (JP) 2021-11-18 US disclosed
US-11060018-B2 Reversibly thermochromic composition and reversibly thermochromic microcapsule pigment encapsulating the same THE PILOT INK CO., LTD. (JP) 2021-07-13 US disclosed
US-20210207146-A1 COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2021-07-08 US disclosed
WO-2012101058-A1 4-TOLYL-ETHYNYL-OCTAHYDRO-INDOLE-1-ESTER DERIVATIVES NOVARTIS AG (CH) 2012-08-02 WO disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20040082578-A1 Arylindenopyridines and related therapeutic and prophylactic methods ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-04-29 US disclosed
EP-0873881-B1 Reversible thermochromic compositions PILOT INK CO LTD (JP) 2001-10-17 EP disclosed
US-5919404-A MIXTURE OF COLOR DEVELOPING COMPOUND AND ELECTRON ACCEPTORALKOXYPHENOL COMPOUND THE PILOT INK CO., LTD. (JP) 1999-07-06 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0873881-A1 Reversible thermochromic compositions The Pilot Ink CO., Ltd. (JP) 1998-10-28 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082578-A1 Arylindenopyridines and related therapeutic and prophylactic methods ADORA2A, ADORA1, PDE2A FAAH 900/4885SLC22A6 2356/4885TSHR 818/4885
US-20260062580-A1 REVERSIBLY THERMOCHROMIC COMPOSITION, REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT ENCAPSULATING REVERSIBLY THERMOCHROMIC COMPOSITION, AND WRITING INSTRUMENT USING REVERSIBLY THERMOCHROMIC MICROCAPSULE PIGMENT TYR, SCO2, HBB FAAH 4333/4885SLC22A6 1997/4885TSHR 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.